EP1003500A4 - Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury - Google Patents

Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Info

Publication number
EP1003500A4
EP1003500A4 EP97938163A EP97938163A EP1003500A4 EP 1003500 A4 EP1003500 A4 EP 1003500A4 EP 97938163 A EP97938163 A EP 97938163A EP 97938163 A EP97938163 A EP 97938163A EP 1003500 A4 EP1003500 A4 EP 1003500A4
Authority
EP
European Patent Office
Prior art keywords
nitric oxide
vascular injury
lesion formation
intramural delivery
oxide enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97938163A
Other languages
German (de)
French (fr)
Other versions
EP1003500A1 (en
Inventor
John P Cooke
Sverin Schwarzacher
Tai T Lim
Alan C Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/695,792 external-priority patent/US5852058A/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of EP1003500A1 publication Critical patent/EP1003500A1/en
Publication of EP1003500A4 publication Critical patent/EP1003500A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
EP97938163A 1996-08-12 1997-08-07 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury Withdrawn EP1003500A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US695792 1996-08-12
US08/695,792 US5852058A (en) 1993-06-11 1996-08-12 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
PCT/US1997/013905 WO1998006389A1 (en) 1996-08-12 1997-08-07 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Publications (2)

Publication Number Publication Date
EP1003500A1 EP1003500A1 (en) 2000-05-31
EP1003500A4 true EP1003500A4 (en) 2004-06-23

Family

ID=24794481

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97938163A Withdrawn EP1003500A4 (en) 1996-08-12 1997-08-07 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Country Status (4)

Country Link
EP (1) EP1003500A4 (en)
JP (1) JP2000516612A (en)
DE (1) DE69637676D1 (en)
WO (1) WO1998006389A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587718B2 (en) 1999-10-08 2003-07-01 Scimed Life Systems, Inc. Iontophoretic delivery to heart tissue
US6706274B2 (en) 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
JP5274248B2 (en) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Nitric oxide releasing particles for nitric oxide therapy and biomedical applications
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
CN102695528B (en) 2009-08-21 2016-07-13 诺万公司 Wound dressing, its using method and forming method thereof
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (en) 2011-02-28 2019-01-02 Novan Inc Silica particles modified with S-nitrosothiol that release nitric oxide and methods of manufacturing them

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483614A1 (en) * 1990-10-30 1992-05-06 Clintec Nutrition Company Use of amino acids for the protection of and metabolic recovery of ischemic cardiac tissue
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
WO1995005866A1 (en) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Simultaneous angioplasty and drug delivery
WO1995024898A1 (en) * 1994-03-17 1995-09-21 Comedicus, Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
WO1996000112A1 (en) * 1994-06-23 1996-01-04 Cormedics Corp. Vascular treatment method and apparatus
WO1997016983A1 (en) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236413B1 (en) * 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5499971A (en) * 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
US5428070A (en) * 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483614A1 (en) * 1990-10-30 1992-05-06 Clintec Nutrition Company Use of amino acids for the protection of and metabolic recovery of ischemic cardiac tissue
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
WO1995005866A1 (en) * 1993-08-27 1995-03-02 Cortrak Medical Inc. Simultaneous angioplasty and drug delivery
WO1995024898A1 (en) * 1994-03-17 1995-09-21 Comedicus, Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
WO1996000112A1 (en) * 1994-06-23 1996-01-04 Cormedics Corp. Vascular treatment method and apparatus
WO1997016983A1 (en) * 1995-11-09 1997-05-15 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9806389A1 *

Also Published As

Publication number Publication date
EP1003500A1 (en) 2000-05-31
JP2000516612A (en) 2000-12-12
WO1998006389A1 (en) 1998-02-19
DE69637676D1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
EP1178727A4 (en) A therapeutic mixture useful in inhibiting lesion formation after vascular injury
ZA974041B (en) Preparation and prevention of fibrotic lesions
IL129315A0 (en) Oxadiazoles process for their preparation and their use as medicaments
EP1080103A4 (en) Compositions and methods for non-parenteral delivery of oligonucleotides
IL128488A0 (en) Inhibiting undesirable taste in oral composition
HUP0100815A3 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
ZA971868B (en) Blends of absorbable polyoxaamides
GB9618420D0 (en) Fatty acid treatment
EP1123102A4 (en) Method of preventing acute lung injury
GB0015235D0 (en) Compositions for the treatment of skin and anorectal conditions
IL129089A0 (en) New derivatives from piperidine-keto acid their preparation and use
EP1015014A4 (en) Methods and compositions for inhibiting angiogenesis
IL130150A0 (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
PL328074A1 (en) Therapeutical method and pharmaceutic composition
EP1003500A4 (en) Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
IL129892A0 (en) Prodrug forms and new analogues of camptothecin and their use as medicaments
EP0918767A4 (en) Pharmaceutical for treating of neurological and neuropsychiatric disorders
EP0675119A3 (en) Preparation of substantially anhydrous propylene oxide.
GB9611180D0 (en) Treatment of vascular lesions
PL331263A1 (en) Derivatives of glyoxylic acid
HUP0002012A3 (en) Use of desferriexochelin for the preparation of pharmaceutical compositions treating atherosclerosis and vascular injury
IL131666A0 (en) Novel carboxylic acid derivatives their preparation and use in treating cancer
HUP0104509A3 (en) Angiogenesis inhibiting nitroaryl-derivatives process for their preparation and their use
GB9621373D0 (en) Fatty acid treatment
HUP0001097A3 (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040507

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61N 1/30 B

Ipc: 7A 61M 29/02 B

Ipc: 7A 61M 25/10 B

Ipc: 7A 61K 31/195 A

17Q First examination report despatched

Effective date: 20061219

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090408